Dateline Introduction
San Diego, CA & Toronto, Canada — November 19, 2025 — Aptose Biosciences Inc. has entered into a definitive Arrangement Agreement under which Hanmi Pharmaceutical Co. Ltd. will acquire all outstanding common shares of Aptose not already owned by Hanmi or its affiliates, marking a significant consolidation in the oncology-focused biopharmaceutical sector. The transaction values Aptose minority shares at C$2.41 per share, representing a 28% premium over the company’s 30-day VWAP, and enables uninterrupted advancement of the company’s lead acute myeloid leukemia (AML) candidate tuspetinib (TUS) as development progresses within the TUSCANY Phase 1/2 clinical program.
Science Significance
The scientific significance of the acquisition centers on the continued development of tuspetinib, a once-daily oral precision kinase inhibitor with activity against SYK, FLT3, KIT, JAK1/2 and RSK2, and designed to avoid many typical toxicities seen with other agents. Clinical data from the ongoing TUSCANY trial show high complete-remission rates and minimal residual disease negativity, including in patients with difficult-to-treat mutations such as TP53, RAS and FLT3, highlighting the compound’s potential to address genetically diverse AML profiles. Hanmi’s full integration of Aptose’s scientific program ensures uninterrupted momentum for triplet therapy development combining TUS with azacitidine and venetoclax, a strategy designed to improve outcomes for newly diagnosed AML patients not eligible for induction chemotherapy.
Advertisement
Regulatory Significance
From a regulatory perspective, the proposed acquisition positions the tuspetinib program for more robust and well-resourced GCP-aligned development, supported by Hanmi’s global regulatory infrastructure and long history of advancing oncology products through major regulatory authorities. The transition from Aptose’s corporate structure to Hanmi’s oversight includes continuation under the Business Corporations Act (Alberta) and a structured plan-of-arrangement that anticipates shareholder approval, court approval and compliance with MI 61-101 minority-protection requirements. With a pivotal expansion of the TUSCANY trial anticipated, Hanmi’s involvement strengthens regulatory preparedness, supports future multinational filings and enhances the long-term IND, CMC and compliance framework essential for late-stage oncology development.
Business Significance
The acquisition represents a major business milestone for both companies. For Aptose, it secures financial stability, removes capital-raising uncertainty and ensures continuity of its clinical programs, especially after Hanmi previously supplied over US$30 million in debt facilities to sustain TUS development. For Hanmi, the deal establishes a direct North American presence, providing a strategic foothold for future partnerships, clinical expansion and commercialization pathways. As Aptose transitions to a private subsidiary under Hanmi, the acquisition strengthens Hanmi’s oncology portfolio and deepens its long-term investment in precision medicines targeting hematologic malignancies. The premium paid to minority shareholders underscores the perceived value of Aptose’s clinical progress and intellectual property assets.
Patients’ Significance
For patients, the deal promises uninterrupted progress toward bringing a potentially life-changing therapy to individuals with AML, a rapidly progressive disease with limited frontline options for many patients. Continued development of TUS+VEN+AZA triplet therapy may yield improved remission rates, deeper molecular responses and better outcomes for genetically diverse or high-risk AML populations. Hanmi’s manufacturing capabilities and clinical infrastructure also may accelerate timelines for future trial expansion, broader patient access and eventual commercialization, offering hope for advanced treatment options where unmet medical need remains high.
Policy Significance
From a policy standpoint, this acquisition highlights the increasing role of cross-border biopharma consolidation in advancing high-risk, high-reward oncology programs. The need for adherence to minority-shareholder protection policies, compliance with MI 61-101, and rigorous conflict-of-interest governance reflects strengthening regulatory expectations in complex M&A transactions involving clinical-stage assets. Moreover, as governments and health systems seek improved outcomes for hematologic malignancies, consolidation of R&D efforts behind promising therapies like tuspetinib aligns with broader public-health goals focused on innovation, patient access and accelerated therapeutic development.
In summary, the acquisition of Aptose Biosciences by Hanmi Pharmaceutical marks a strategically significant moment for both companies and for AML therapeutic innovation. The transaction provides the financial and operational stability required to advance tuspetinib through its ongoing clinical program while granting Hanmi a robust scientific asset and a strategic North American platform. As the transaction moves toward completion pending shareholder and court approvals, it underscores the importance of sustained investment, regulatory discipline and scientific collaboration in driving the next generation of precision oncology therapies.
Source: Aptose Biosciences, Inc. press release
